ReposiTrak Adds 50 New Food and Beverage Suppliers to the Queue for the Rapidly Expanding Food Traceability Network

SALT LAKE CITY--(BUSINESS WIRE)--ReposiTrak (NYSE:TRAK), the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, is proud to add 50 food and beverage suppliers to the queue of companies joining the ReposiTrak Traceability Network® (RTN). These companies will efficiently exchange intricate, FDA-required Key Data Elements (KDEs) for each Critical Tracking Event (CTE) in their supply chains, with the goal of meeting the growing traceability demands of their retail customers.
Among the 50 new suppliers are many whose customers require traceability for all foods, not only Food Traceability List foods. One is a company known for providing nuts, confections, and nostalgic snacks for more than 80 years. Another, founded more than 150 years ago, has deep roots in the snack food sector with their iconic cookies and crackers. A third began in the early 1970s and has grown into a global leader in specialty coffee, offering a wide range of premium beverages, packaged drinks and coffee products available in retail stores worldwide.
'Suppliers large and small can use ReposiTrak to share traceability data with their retail customers in the exact format those customers require,' stated Randy Fields, chairman and CEO of ReposiTrak. 'We run every traceability data file through a 500+ point error detection process, to ensure it meets both FDA regulations and the often-stricter requirements of retail partners, removing complexity and reducing the risk of noncompliance.'
The ReposiTrak Traceability Network requires no additional hardware or software and the ReposiTrak team assists in making the connections needed under the new regulation. Suppliers can connect to an unlimited number of trading partners and share data for a low, flat fee.
About ReposiTrak
ReposiTrak (NYSE: TRAK) provides retailers, suppliers, food manufacturers and wholesalers with a robust solution suite to help reduce risk and remain in compliance with regulatory requirements, enhance operational controls and increase sales with unrivaled brand protection. Consisting of three product families – food traceability, compliance and risk management and supply chain solutions – ReposiTrak's integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit https://repositrak.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

35 minutes ago

• Business Insider

Nisource (NI) Gets a Buy from BMO Capital

In a report released on June 18, James Thalacker from BMO Capital maintained a Buy rating on Nisource (NI – Research Report), with a price target of $44.00. The company's shares closed last Friday at $39.52. Confident Investing Starts Here: Thalacker covers the Utilities sector, focusing on stocks such as American Electric Power, Centerpoint Energy, and CMS Energy. According to TipRanks, Thalacker has an average return of 13.4% and a 64.52% success rate on recommended stocks. In addition to BMO Capital, Nisource also received a Buy from Jefferies's Julien Dumoulin Smith in a report issued on June 10. However, on June 3, Citi assigned a Hold rating to Nisource (NYSE: NI). NI market cap is currently $18.6B and has a P/E ratio of 21.29. Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NI in relation to earlier this year. Earlier this month, Melanie B. Berman, the EVP Administration & CHRO of NI sold 6,227.00 shares for a total of $245,468.34.

The Hill

an hour ago

• The Hill

Thanks to imported drugs, America has lost control of its medicine cabinet

America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicines. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe. At the root of it is a hard truth: We no longer have control of the medicines we depend on every day. In 2002, America manufactured 83.7 percent of the pharmaceuticals it consumed. By 2024, that number had dropped to just 37.1 percent. Meanwhile, the U.S. pharmaceutical trade deficit has soared, reaching a record $118.3 billion in 2024. We didn't just outsource manufacturing — we outsourced the sovereignty and safety of our health care system. This means that nearly two-thirds of America's pharmaceutical supplies are now imported. Most critical medications, such as generic drugs, now come from China and India. China controls 80 to 90 percent of the global supply of active pharmaceutical ingredients — the chemical building blocks of modern medicine. Even drugs labeled 'Made in the USA' often chemically originate in China. And India, which produces about half of America's finished generic drugs, relies on China for up to 80 percent of its active pharmaceutical not a supply chain — it's a ticking time something goes wrong, American patients suffer. In 2023, the Food and Drug Administration shut down a single Indian plant responsible for 50 percent of the U.S. supply of cisplatin, a critical chemotherapy drug, after uncovering a 'cascade of failure' in safety practices and shredded documents soaked in acid. With no domestic backup, patients nationwide had their treatments delayed. That wasn't a fluke. 40 percent of U.S. generic drugs have only one FDA-approved manufacturer. Because of that single chokepoint, when one factory fails, the whole system can crack. We are now seeing widespread drug shortages across the medical system. Hospital pharmacists report an average of 301 critical drug shortages at any given time. And 85 percent say these shortages are moderately or critically affecting care. Doctors often lack crucial medicines such as antibiotics, sedatives and cancer drugs. These aren't obscure drugs. They're foundational medicines. But America no longer makes them. Even when imported drugs do arrive, they're not always safe. A 2025 study found that Indian generics are 54 percent more likely to cause serious side effects than their U.S.-made counterparts. Indian factory violations have also been tied to at least eight U.S. patient deaths. China's record is equally disturbing. In 2008, dozens of Americans died after receiving contaminated heparin from Chinese suppliers. This isn't what the American people want. In a national survey, 85 percent of hospital pharmacists said they would pay more for safer generics. But under today's rules, price overshadows quality. Hospitals have little oversight of drug quality — and foreign producers face few consequences for cutting corners. Even the federal government is flying blind. A 2023 Department of Defense review found that 22 percent of essential military-use drugs had unknown ingredient sourcing. That's a national security April, the Trump administration took a necessary step by launching an investigation into generic pharmaceutical imports that correctly frames the issue as a national security threat. But that recognition alone isn't enough. To address this crisis, Washington should impose targeted tariffs on generic drugs from adversarial nations. It must also rebuild domestic pharmaceutical production through tax credits and long-term contracts. America urgently needs full transparency in drug labeling to disclose where drugs and their ingredients are made. The FDA must step up — with stronger enforcement abroad and a ban on imports from repeat safety violators. And to secure critical ingredients during market disruptions, Washington must pursue a long-term vision that includes a 'strategic pharmaceutical reserve.' This isn't just protectionism. It's a restoration of America's medical security. No nation can call itself sovereign if it can't produce its own medicines, and no patient is safe if their health care depends on quality control in a factory 8,000 miles decades, we were told that offshoring production would make things cheaper, smoother and more efficient. But America can no longer depend on unstable foreign suppliers. It's time to restore our pharmaceutical independence and take back control of our medicine cabinet. Andrew Rechenberg is an economist at the Coalition for a Prosperous America.

Yahoo

an hour ago

• Yahoo

This Ultra-High Dividend Yield Stock Is Crushing the Market in 2025: But Is It a Buy Today?

Altria's cigarette volume declines are accelerating, but it's maintaining earnings growth through price increases. The company is trying to grow with new nicotine products, but it has struggled against the competition. The stock has a high dividend yield, but the business looks to be at risk over the next 10 years. 10 stocks we like better than Altria Group › In times of turmoil and uncertainty, investors often flock to consumer staples. That has occurred yet again in 2025. Altria Group (NYSE: MO) has posted a total return of 17% year to date, compared to a measly 2% return for the S&P 500 index. With domestic rights to the tobacco brand Marlboro, among other assets, the company has long been a reliable dividend stock, and it boasts a sky-high dividend yield of 6.8% as of this writing. Should you buy shares of Altria Group to ride out market volatility? Here are the positives and negatives of owning the tobacco stock right now. The largest selling point against Altria Group and its cigarette business is the rapidly declining usage of cigarettes in the United States. While good for society, it is a headwind to Altria's bottom line, with gradually declining demand for the company's core product. And this trend may be accelerating as Marlboro volumes fell 13% year over year last quarter, one of the worst volume performances in the company's history. Altria has been able to counteract volume declines with price increases. Smokeable net revenue after excise taxes only dipped 4.1% last quarter with operating income up 1.2% to $2.47 billion. Altria has long been able to prop up its bottom line despite the shrinking pool of smokers in the United States. It reported $11.62 billion of consolidated operating income over the past 12 months, a figure that has held relatively steady over the last five years. Just because cigarette usage in the U.S. is declining, however, does not mean nicotine usage is down. New forms of nicotine consumption have popped up in recent years, such as electronic vapor and tobacco-free nicotine pouches. Altria has made numerous investments into these product categories. It now owns the NJOY vaping brand, which is growing market share in the U.S. (6.6% as of last quarter). Revenue and earnings from NJOY are not disclosed today, but it is a growing brand for Altria that can help make up for lost cigarette customers. Altria also owns the On! pouch brand, which grew shipment volumes 18% last quarter to 39.3 million. One problem remains, though: It's well behind other tobacco giants in building these new nicotine businesses. For example, On! competitor Zyn, owned by Philip Morris International, is growing faster and has much larger market share. Zyn shipment volume in the United States was 202 million last quarter, up from 132 million a year ago. That means Zyn added more than the entire quarterly On! shipment volume in just one year. Altria is behind its peers in non-tobacco nicotine, and that's not a great place for the business to be in. Altria's dividend currently yields 6.8%, enough to generate a substantial amount of annual income. For example, if you own $10,000 of Altria stock, you would receive about $680 in dividend income for the year (before taxes). That amount will likely grow over time as well. But how sustainable is this dividend with the company facing weakening demand for its biggest product? Altria pays an annualized dividend per share of $4.04, while its free cash flow per share is $4.97, or 23% larger than the payout. Free cash flow is the core metric here since it represents the company's operating cash flow, less capital expenditures (money reinvested into the business). The cushion between Altria's dividend payments and free cash flow leaves it with some flexibility to maintain and grow its annual payout. At the same time, management is repurchasing stock, which reduces its outstanding share count and the total amount paid out in dividends each quarter. So, in the short run, Altria Group should have no trouble maintaining its dividend, but it's the long run that concerns me. Record cigarette volume declines will catch up with the company eventually, and anyone looking to hold the stock for years of steady, passive income is facing this major risk. That's why I suggest avoiding Altria Group stock, even with its market-beating yield. Before you buy stock in Altria Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Altria Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool recommends Philip Morris International. The Motley Fool has a disclosure policy. This Ultra-High Dividend Yield Stock Is Crushing the Market in 2025: But Is It a Buy Today? was originally published by The Motley Fool Sign in to access your portfolio